Close Menu

CHICAGO – In the dawning age of precision oncology, bioinformatics has become indispensable to cancer research, and will continue to grow in importance, according to National Cancer Institute (NCI) Director Norman "Ned" Sharpless.

"I think the cancer research enterprise has really come to a point where the integration of data science into our work is critical," Sharpless said during a keynote address to the virtual American Medical Informatics Association (AMIA) Informatics Summit this week.

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sponsored by

Cancer is a complex and heterogeneous disease requiring patient-specific molecular analysis to support treatment decisions.

Sponsored by
Canexia Health

Last year, by Precision Oncology News' count, the FDA approved 27 precision oncology drugs, a 35 percent increase in the number of approvals from 2019.